

November 22, 2021

For more information:  
Sharon Polk  
913-221-5834

## Research shows lame dogs with joint deterioration are referred late, reducing successful treatment

*Exubrion offers new portal for information on elbow OA diagnosis, treatment*

Buford, Georgia – Veterinarians specializing in canine osteoarthritis (OA) treatments would like to see patients sooner, according to new research conducted among specialists. They believe an earlier referral could yield better outcomes. Veterinary specialists believe most canine elbow osteoarthritis patients received referrals too late – when the dog is at a moderate to severe stage of OA.

The research was conducted in Summer 2021 with 68 veterinary specialists who routinely received referrals from general practitioners for canine patients with lameness and pain due to osteoarthritis.

“Nearly one in four dogs suffer from osteoarthritis<sup>1</sup> causing pain, lameness, limping, limited movement and a poor quality of life, explained Dr. John ‘Jay’ Donecker, chief veterinary officer of Exubrion, who initiated the research. “Earlier referrals for many of these canine patients could result in less pain and better quality of life for these beloved pets.”

### Additional research findings revealed:

- Nearly 100% of specialists (66/68) believe that earlier referrals would result in better treatment outcomes, primarily because they believe early intervention slows the progression, reducing the severity of elbow OA.
- In addressing this issue, specialists wish GPs knew more about examination clues, availability of treatment options if diagnosed early, and were better able to recognize early radiographic signs of OA.
- Close to three-fourths (48/68) of specialists strongly believe that treating inflammation is paramount in controlling elbow OA.
- Specialists contend the biggest reason, by far, that late-stage referrals are less successful is that the joint’s structural changes are too significant and have progressed too far.

### Addressing the need for more information and training

“Beyond encouraging earlier referrals, we want to help general practitioners by providing tools and information to help with elbow OA diagnosis and treatment options” explained Donecker. A new website, [k9elbowroom.com](http://k9elbowroom.com), is a gateway to additional information.

### Within the website, general practitioners can find:

- Inflammatory cycle overview
- Assessment for canine elbow arthritis



Specialists believe earlier referrals would result in better outcomes



Nearly 75% of specialists believe treating inflammation is paramount to controlling elbow OA

- Videos on how to diagnose elbow OA
- Information on new treatment options, including the new treatment Synovetin OA<sup>®</sup>, which is a minimally invasive treatment that is placed in the dog's elbow that reduces inflammation and pain of osteoarthritis for up to one full year
- Opportunity to submit information about recently diagnosed cases within the GP practice for information sharing purposes

"We want dogs suffering from pain, lameness, and reduced activity due to elbow arthritis to receive the proper diagnosis and treatment," Dr. Donecker continued. "We hope they'll be treated with Synovetin OA<sup>®</sup>, but are interested in timely and effective treatment for all canine patients. Many dogs suffer needlessly because their pain isn't adequately managed by current therapies."

Matt Brunke, DVM and medical director for Veterinary Surgical Centers in Northern Virginia, has treated more than 50 dogs with Synovetin OA. "Synovetin OA is a minimally invasive treatment placed right in the dog's elbow," Brunke said. "It reduces the inflammation and pain of osteoarthritis for up to one full year. Common treatments require daily administration to provide short-term relief. Synovetin OA has been an excellent addition to our practice."

Clinical trial data has shown that just one simple treatment with Synovetin OA can relieve pain and inflammation and improves mobility for up to one full year. Synovetin OA was developed by Exubrion Therapeutics<sup>®</sup>.

## Technical Details of Synovetin OA

Synovetin OA breaks the cycle of pain with just one treatment, clinically improving mobility and providing proven relief for up to one full year. The active agent of Synovetin OA is tin-117m, a unique medical radiotherapeutic. Synovetin OA:

- Reduces inflammation and relieves chronic canine elbow OA pain
- Breaks the cycle of pain and inflammation that drives OA progression
- Is administered just once a year and can be re-administered again after a year, if needed
- Is safe; no significant clinical side effects were seen during clinical trials
- Is given in the hospital and the dog can normally return home the same day
- Can be considered along with other treatments for OA pain management, if needed
- May offer pet owner convenience by eliminating daily dosing

Synovetin OA effectiveness and safety were demonstrated in three multi-center studies, showing a 92 percent (13/14) treatment success rate over 12 months in dogs with elbow OA that was determined to be mild or moderate in severity. 71% (10/14) of dogs with severe elbow OA were considered treatment successes.

This procedure can only be performed by licensed veterinarians at veterinary hospitals permitted to use internal radiation therapy. On rare occasions, discomfort in the treated elbow has been seen in dogs that can last up to 72 hours after treatment. Short-term homecare instructions must be followed after treatment to minimize extended close contact such as co-sleeping. To review the full veterinary prescribing information, visit [synovetin.com/cpinfo](http://synovetin.com/cpinfo).

## About Exubrion

**Our vision is to forever improve the compassionate care of companion animals. Our name, Exubrion, emerged from the word "exuberance," which is the quality of being full of energy and excitement. "Exubrion" speaks to our determination to help animals live healthy, active, and pain-free lives.**